Camp4 CEO awarded 580,000 stock options
Camp4 Therapeutics Corp reported that Chief Executive Officer Josh Mandel-Brehm received a grant of stock options on Common Stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Camp4 Therapeutics Corp reported that Chief Executive Officer Josh Mandel-Brehm received a grant of stock options on Common Stock. The award covers 580,000 shares with an exercise price of $4.46 per share and an expiration date of March 31, 2036.
The options vest in equal monthly installments over four years starting from the grant date, meaning the award is earned gradually over time. Following this grant, Mandel-Brehm holds stock options covering 580,000 shares directly.
Insider Trade Summary
Grant/Award: 580,000 shares
Grant/Award
1 txn
Insider
Mandel-Brehm Josh
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 580,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 580,000 contracts (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 580,000 contracts (Direct)
Footnotes (1)
- F1. The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant.
Key Figures
Option grant size: 580,000 shares
Exercise price: $4.46 per share
Expiration date: March 31, 2036
+3 more
6 metrics
Option grant size
580,000 shares
Stock Option (Right to Buy) granted to CEO on April 1, 2026
Exercise price
$4.46 per share
Conversion or exercise price of stock option
Expiration date
March 31, 2036
Option expiration for CEO stock option grant
Underlying common shares
580,000 shares
Common Stock underlying the granted stock option
Post-grant option holdings
580,000 options
Total stock options held directly by CEO after transaction
Vesting schedule
4 years monthly
Vests in equal monthly installments over four years from grant date
Key Terms
Stock Option (Right to Buy), conversion or exercise price, expiration date, Common Stock, +2 more
6 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
conversion or exercise price financial
"conversion_or_exercise_price: 4.4600"
expiration date financial
"expiration_date: 2036-03-31T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
vest in equal monthly installments financial
"The shares underlying the option vest in equal monthly installments over a period of four years"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Camp4 Therapeutics (CAMP) disclose about Josh Mandel-Brehm’s equity award?
Camp4 Therapeutics disclosed that CEO Josh Mandel-Brehm received a stock option grant for 580,000 shares of Common Stock. The options have a $4.46 exercise price and expire on March 31, 2036, forming part of his long-term equity compensation.
How many Camp4 Therapeutics (CAMP) options were granted to the CEO?
Josh Mandel-Brehm was granted stock options covering 580,000 shares of Camp4 Therapeutics Common Stock. This entire amount is reflected as held directly after the grant, indicating a new equity-based incentive aligned with the company’s long-term performance.
What is the exercise price and term of the CAMP CEO’s stock options?
The CEO’s stock options have a $4.46 per share exercise price and expire on March 31, 2036. This means he can choose to purchase shares at $4.46 any time before that expiration date, once the options have vested.
How do Josh Mandel-Brehm’s Camp4 Therapeutics options vest over time?
The options granted to Josh Mandel-Brehm vest in equal monthly installments over four years from the grant date. This structure rewards continued service, as more of the 580,000 underlying shares become exercisable each month across the four-year period.
Did the Camp4 Therapeutics (CAMP) CEO buy or sell any common stock in this filing?
The filing shows a grant of stock options, not an open-market stock purchase or sale. It records an acquisition of derivative securities (options) as compensation, with no reported buying or selling of Camp4 Therapeutics Common Stock in the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
